Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV002537887 | SCV003266448 | benign | Sphingolipid activator protein 1 deficiency | 2025-01-08 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV003355353 | SCV004050827 | uncertain significance | Inborn genetic diseases | 2023-06-29 | criteria provided, single submitter | clinical testing | The c.1137G>C (p.E379D) alteration is located in exon 10 (coding exon 10) of the PSAP gene. This alteration results from a G to C substitution at nucleotide position 1137, causing the glutamic acid (E) at amino acid position 379 to be replaced by an aspartic acid (D). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |
Mayo Clinic Laboratories, |
RCV003481049 | SCV004225276 | uncertain significance | not provided | 2023-03-01 | criteria provided, single submitter | clinical testing | BP4, PM2 |
Natera, |
RCV001280270 | SCV001467435 | uncertain significance | Metachromatic leukodystrophy | 2020-04-11 | no assertion criteria provided | clinical testing |